Key Highlights:
- Bexorg’s pioneering whole-brain perfusion technology enables unprecedented preclinical insights by restoring metabolic activity in isolated human brains.
- The collaboration with Biohaven aims to de-risk and fast-track two CNS preclinical drug programs using AI-powered biomarker and pharmacology data.
- This breakthrough platform addresses long-standing translational gaps in CNS drug discovery, promising more precise and efficient clinical outcomes.
Strategic Collaboration to Transform CNS Therapeutics
Bexorg, a techbio innovator focused on decoding the human brain, has entered a multi-program research collaboration with Biohaven Ltd. Leveraging Bexorg’s unique AI-driven whole-brain discovery platform, the partnership targets enhanced identification and validation of next-generation CNS therapies. This initiative supports Biohaven’s preclinical pipeline with novel biomarker development and mechanistic insights.
Revolutionary Whole-Brain Discovery Platform
Bexorg’s platform is the only technology capable of perfusing isolated human and pig brains with artificial blood to restore metabolic and molecular activity for extended periods. Developed at Yale University, this platform captures high-resolution transcriptomic, proteomic, and metabolic data in disease-relevant states, creating the largest physiologically relevant datasets for AI-enabled CNS drug discovery.
AI-Powered Insights Driving Drug Development
By applying advanced machine learning to its datasets, Bexorg accelerates the understanding of CNS disorders at the molecular level. This allows longitudinal validation of drug targets and biomarkers, optimizing pharmacokinetic and pharmacodynamic profiles before clinical trials. The collaboration promises a faster, safer, and more precise route for CNS drug candidates.
Overcoming Translational Challenges in CNS Research
Traditional preclinical CNS models fail to replicate the brain’s complexity and drug distribution dynamics. According to Biohaven’s Chief Scientific Officer Bruce D. Car, Bexorg’s platform addresses these critical gaps, offering unprecedented insights into CNS pharmacology and drug efficacy, thereby reducing the risk and cost of clinical development.
About Bexorg:
Bexorg, Inc. is a pioneering techbio company dedicated to advancing central nervous system (CNS) drug discovery through its novel whole-brain discovery platform. Originating from groundbreaking research at Yale University, Bexorg’s technology restores metabolic activity in isolated human and pig brains, enabling unprecedented insights into brain biology and disease. By combining this platform with advanced AI and machine learning, Bexorg aims to transform CNS therapeutic development, providing more predictive and translatable preclinical models to accelerate drug discovery and improve patient outcomes.
About Biohaven:
Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on developing and commercializing innovative therapies for neurological and neuropsychiatric diseases. With a strong pipeline targeting migraine, CNS disorders, and rare diseases, Biohaven is committed to improving the lives of patients through science-driven, patient-centric drug development. The company actively pursues strategic collaborations and cutting-edge technologies to advance its mission of delivering transformative treatments to address unmet medical needs.
By
